LOGIN  |  REGISTER
Cue Biopharma

Eli Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement

November 29, 2022 | Last Trade: US$827.54 9.52 1.16

INDIANAPOLIS, Nov. 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial guidance.

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.

About Lilly

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn. F-LLY

Refer to:

Jordan Bishop; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-473-5712 (Media)

 

Joe Fletcher; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-296-2884 (Investors)

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page